Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for detecting presence of severe acute respiratory syndrome coronavirus 2 in biological sample

A technology for respiratory syndrome and biological samples, applied in the field of real-time identification of pathogenic microorganisms and/or their antibiotic resistance

Pending Publication Date: 2022-08-05
TELEFLEX MEDICAL INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While some tests exist, these can take days to provide results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detecting presence of severe acute respiratory syndrome coronavirus 2 in biological sample
  • Method for detecting presence of severe acute respiratory syndrome coronavirus 2 in biological sample
  • Method for detecting presence of severe acute respiratory syndrome coronavirus 2 in biological sample

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] One aspect of this disclosure involves a method for detecting severe acute respiratory syndrome Coronatte 2 (SARS-COV-2) in biological samples (SARS-COV-2), which includes the following steps Cracks; the target nucleic acid sequences in the crack -based nucleic acid sequence (NASBA) are generated by existing the existence of positive primers, reverse primers and molecular beaches to generate expanded cracks. The positive primer has the oligonucleotide sequence of a group composed of a group of groups composed of a group composed of a group composed of a group. The reverse primer has the oligonucleotide sequence of the group of groups composed of a group. The molecular label has the oligonucleotide sequence and fluorescent group of the seq ID NO: 3, SEQ ID NO: 7, SEQID NO: 11, SEQ ID NO: 15, and SEQ ID NO: 19. The exposure of the exposure of the extension is exposed to the source of the excitement. Detects the fluorescence of fluorescent groups exposed to exposed to the exci...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for detecting the presence of SARS-CoV-2 in a biological sample, comprising: subjecting the biological sample to cleavage to form a lysate; generating an amplified lysate by nucleic acid sequence (NASBA)-based amplification of a target nucleic acid sequence in the lysate in the presence of a forward primer having an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13 and SEQ ID NO: 17, a reverse primer, and a molecular beacon; the reverse primer has an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14 and SEQ ID NO: 18; the molecular beacon has an oligonucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, and SEQ ID NO: 19, and a fluorophore; exposing the amplified lysate to an excitation source; detecting fluorescence of a fluorophore in the amplified lysate exposed to the excitation source; in response to detecting the fluorescence of the fluorophore, it is determined whether SARS-CoV-2 is present in the biological sample.

Description

[0001] Cross reference for related applications [0002] This application requirement enjoys the preferred right of temporary patent application number 63 / 017043 and August 10, 2020, which is submitted to the US temporary patent application number 63 / 063731 submitted on April 29, 2020. This application is September 4, 2020 Part of the PCT international patent application PCT / US20 / 49394 continues to apply. Together in this article in a full text. Technical field [0003] The invention generally involves the method of identifying pathogenic microorganisms. More specifically, the present invention involves, for example, a nucleic acid sequence -based amplifier (NASBA) using a specific RNA sequence (NASBA) in real -time identification pathogenic microorganisms and / or its antibiotic resistance in biological samples. Background technique [0004] The new coronary virus (SARS-COV-2) that leads to COVID 19 is the cause of global infection and is currently classified as an epidemic. Althou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/70C12Q1/6844C12N15/11
CPCC12Q1/701C12Q1/6844C12Q2531/143C12Q2563/107C12Q2527/125C12Q1/70C12Q2600/16B01L2200/0663
Inventor 迈克尔·布查德史蒂文·布吕泽克切尔西·科纳普劳伦·麦克丹尼尔杰西卡·斯莫罗伯特·乌尔里希维多利亚·瓦格纳
Owner TELEFLEX MEDICAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com